356 related articles for article (PubMed ID: 22489043)
1. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
[TBL] [Abstract][Full Text] [Related]
2. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
[TBL] [Abstract][Full Text] [Related]
3. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
4. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic alterations of myeloproliferative disorders.
Milosevic JD; Kralovics R
Int J Hematol; 2013 Feb; 97(2):183-97. PubMed ID: 23233154
[TBL] [Abstract][Full Text] [Related]
6. Molecular aspects of myeloproliferative neoplasms.
Delhommeau F; Jeziorowska D; Marzac C; Casadevall N
Int J Hematol; 2010 Mar; 91(2):165-73. PubMed ID: 20186505
[TBL] [Abstract][Full Text] [Related]
7. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative neoplasms: Current molecular biology and genetics.
Saeidi K
Crit Rev Oncol Hematol; 2016 Feb; 98():375-89. PubMed ID: 26697989
[TBL] [Abstract][Full Text] [Related]
9. Genetics of the myeloproliferative neoplasms.
Abdel-Wahab O
Curr Opin Hematol; 2011 Mar; 18(2):117-23. PubMed ID: 21307773
[TBL] [Abstract][Full Text] [Related]
10. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
11. TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms.
Soyer N; Tezcanlı Kaymaz B; Cömert Özkan M; Aktan Ç; Küçükaslan AŞ; Şahin F; Kosova B; Saydam G
Turk J Haematol; 2017 Jun; 34(2):174-178. PubMed ID: 28218607
[TBL] [Abstract][Full Text] [Related]
12. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
[TBL] [Abstract][Full Text] [Related]
13. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W; Kralovics R
Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
[TBL] [Abstract][Full Text] [Related]
14. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
[TBL] [Abstract][Full Text] [Related]
16. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.
Makishima H; Jankowska AM; McDevitt MA; O'Keefe C; Dujardin S; Cazzolli H; Przychodzen B; Prince C; Nicoll J; Siddaiah H; Shaik M; Szpurka H; Hsi E; Advani A; Paquette R; Maciejewski JP
Blood; 2011 May; 117(21):e198-206. PubMed ID: 21346257
[TBL] [Abstract][Full Text] [Related]
17. New mutations and pathogenesis of myeloproliferative neoplasms.
Vainchenker W; Delhommeau F; Constantinescu SN; Bernard OA
Blood; 2011 Aug; 118(7):1723-35. PubMed ID: 21653328
[TBL] [Abstract][Full Text] [Related]
18. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Tefferi A; Lasho TL; Abdel-Wahab O; Guglielmelli P; Patel J; Caramazza D; Pieri L; Finke CM; Kilpivaara O; Wadleigh M; Mai M; McClure RF; Gilliland DG; Levine RL; Pardanani A; Vannucchi AM
Leukemia; 2010 Jul; 24(7):1302-9. PubMed ID: 20508616
[TBL] [Abstract][Full Text] [Related]
19. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
20. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
